Vanguard Global Advisers
BBNX

Vanguard Global Advisers’s Beta Bionics BBNX Stock Holding History

Vanguard Global Advisers’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Hold
15,558
– – ﹤0.01% 2422
2026
Q1 		$156K Buy
+15,558
New +$230K ﹤0.01% 2548

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Global Advisers's BBNX Position: Q2 2026 in Review

Vanguard Global Advisers held its Beta Bionics (BBNX) position steady in Q2 2026 at 15,558 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Vanguard Global Advisers first reported a position in BBNX in Q1 2026 and has held it in 2 quarters since. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Vanguard Global Advisers held 15,558 shares of Beta Bionics worth $244K as of Q2 2026.
  • Vanguard Global Advisers left its Beta Bionics share count unchanged in Q2 2026.
  • Beta Bionics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2422 holding.
  • Vanguard Global Advisers first reported a position in Beta Bionics in Q1 2026 and has held it in 2 quarters since.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.